Discussion This case illustrates the critical role of addressing metabolic and autoimmune drivers of HT, especially since TSH and anti-TPO antibodies are key markers of insulin resistance, in addition to levothyroxine.5 In assessing the four-month outcome of the case of improved thyroid function, decreased thyroid antibodies, and improved insulin resistance, there are specific pathways that would have been addressed by tirzepatide alone
Baseline estimated renal function was normal (eGFR 90 mL/min/1.73m2) in 66.2%, mildly impaired (eGFR 60 to 90 mL/min/1.73m2) in 32.4% and moderately impaired (eGFR 30 to 60 mL/min/1.73m2) in 1.4% of patients
Clinical Trial Results The SURMOUNT clinical trial program evaluated Tirzepatide specifically for weight management in people without diabetes
This guide covers the common and rare side effects of tirzepatide injections, the biological reasons they occur, and practical strategies to manage them effectively
Once the medication is prescribed, your physician will instruct you on how much medication to administer weekly